CN105198790A - 促进双阴性t细胞体外增殖的四环化合物 - Google Patents
促进双阴性t细胞体外增殖的四环化合物 Download PDFInfo
- Publication number
- CN105198790A CN105198790A CN201510186837.4A CN201510186837A CN105198790A CN 105198790 A CN105198790 A CN 105198790A CN 201510186837 A CN201510186837 A CN 201510186837A CN 105198790 A CN105198790 A CN 105198790A
- Authority
- CN
- China
- Prior art keywords
- cell
- compound
- car
- cells
- tetracyclic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510186837.4A CN105198790B (zh) | 2015-04-20 | 2015-04-20 | 促进双阴性t细胞体外增殖的四环化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510186837.4A CN105198790B (zh) | 2015-04-20 | 2015-04-20 | 促进双阴性t细胞体外增殖的四环化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105198790A true CN105198790A (zh) | 2015-12-30 |
CN105198790B CN105198790B (zh) | 2018-02-16 |
Family
ID=54946791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510186837.4A Active CN105198790B (zh) | 2015-04-20 | 2015-04-20 | 促进双阴性t细胞体外增殖的四环化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105198790B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109401969A (zh) * | 2018-12-13 | 2019-03-01 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接***及其使用方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1882342A (zh) * | 2003-09-17 | 2006-12-20 | 艾科斯有限公司 | Chk1抑制剂在控制细胞增殖中的应用 |
CN102695413A (zh) * | 2009-11-10 | 2012-09-26 | 麦赛尔控股有限公司 | 稳定的脂肪酸的制剂 |
WO2013049307A2 (en) * | 2011-09-30 | 2013-04-04 | University Of Miami | Enhanced immune memory development by aptamer targeted mtor inhibition of t cells |
WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
CN104136458A (zh) * | 2012-02-22 | 2014-11-05 | 宾夕法尼亚大学董事会 | 在第二代嵌合抗原受体中cd2信号传导结构域的使用 |
WO2015023553A2 (en) * | 2013-08-13 | 2015-02-19 | Bionumerik Pharmaceuticals, Inc. | Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur- containing, amino acid-specific small molecules |
-
2015
- 2015-04-20 CN CN201510186837.4A patent/CN105198790B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1882342A (zh) * | 2003-09-17 | 2006-12-20 | 艾科斯有限公司 | Chk1抑制剂在控制细胞增殖中的应用 |
CN102695413A (zh) * | 2009-11-10 | 2012-09-26 | 麦赛尔控股有限公司 | 稳定的脂肪酸的制剂 |
WO2013049307A2 (en) * | 2011-09-30 | 2013-04-04 | University Of Miami | Enhanced immune memory development by aptamer targeted mtor inhibition of t cells |
CN104136458A (zh) * | 2012-02-22 | 2014-11-05 | 宾夕法尼亚大学董事会 | 在第二代嵌合抗原受体中cd2信号传导结构域的使用 |
WO2014165707A2 (en) * | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
WO2015023553A2 (en) * | 2013-08-13 | 2015-02-19 | Bionumerik Pharmaceuticals, Inc. | Contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of disease by administration of sulfur- containing, amino acid-specific small molecules |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109401969A (zh) * | 2018-12-13 | 2019-03-01 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接***及其使用方法 |
CN109401969B (zh) * | 2018-12-13 | 2024-02-02 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接***及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105198790B (zh) | 2018-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liang et al. | Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity | |
Cheng et al. | Exosomes from melatonin treated hepatocellularcarcinoma cells alter the immunosupression status through STAT3 pathway in macrophages | |
Sakamoto et al. | Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer | |
Marçais et al. | The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells | |
KR102664078B1 (ko) | 환자-유래 이종이식을 가지는 hla-비매칭의 인간화된 nsg 마우스 모델 | |
Casey et al. | IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype | |
CN103756964B (zh) | 一种高效扩增cd3-cd56+的自然杀伤细胞培养***的方法 | |
AU2013379773B2 (en) | Methods of producing enriched populations of tumor reactive T cells from peripheral blood | |
CN104789595A (zh) | 嵌合抗原受体双阴性t细胞的构建方法 | |
CN109294985A (zh) | 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法 | |
Park et al. | Interleukin-21 increases direct cytotoxicity and IFN-γ production of ex vivo expanded NK cells towards breast cancer cells | |
JP2016524914A5 (zh) | ||
Sajid et al. | The dynamic role of NK cells in liver cancers: role in HCC and HBV associated HCC and its therapeutic implications | |
CN106591363A (zh) | 一种通用型异体car‑t细胞制备方法及应用 | |
Li et al. | Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway | |
Kravtsov et al. | Roles of CD4+ T cells as mediators of antitumor immunity | |
Debray et al. | De novo malignancy after solid organ transplantation in children | |
Qiang et al. | Construction of Durvalumab/carbon nanotube/PEI/aptamer-siRNA chimera for the immunotherapy of hepatocellular carcinoma | |
Li et al. | Expansion of granulocytic, myeloid-derived suppressor cells in response to ethanol-induced acute liver damage | |
Chen et al. | Hypofractionated irradiation suppressed the off-target mouse hepatocarcinoma growth by inhibiting myeloid-derived suppressor cell-mediated immune suppression | |
Song et al. | Targeting cytokine signals to enhance γδT cell-based cancer immunotherapy | |
CN105198790A (zh) | 促进双阴性t细胞体外增殖的四环化合物 | |
JP2022023136A5 (zh) | ||
CN107502589A (zh) | 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法 | |
Baron et al. | Clinical manufacturing of regulatory T cell products for adoptive cell therapy and strategies to improve therapeutic efficacy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190808 Address after: Room 411, Building 15, No. 8, Jinfeng Road, Suzhou High-tech Zone, Jiangsu Province Patentee after: Suzhou pharos Biological Medicine Technology Co.,Ltd. Address before: Room 802, Building 7, 300 Lane, Jinxiu Road, Pudong New Area, Shanghai 200000 Patentee before: Fan Guohuang |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200628 Address after: Room 402, building 8, 760 xinjunhuan Road, Minhang District, Shanghai, 201100 Patentee after: Anmengde Pharmaceutical Technology (Shanghai) Co.,Ltd. Address before: Room 411, Building 15, No. 8, Jinfeng Road, Suzhou High-tech Zone, Jiangsu Province Patentee before: Suzhou pharos Biological Medicine Technology Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 402, building 8, 760 Xinjun Ring Road, Minhang District, Shanghai 201100 Patentee after: Aimeifei Biopharmaceutical Technology (Shanghai) Co.,Ltd. Address before: Room 402, building 8, 760 Xinjun Ring Road, Minhang District, Shanghai 201100 Patentee before: Anmengde Pharmaceutical Technology (Shanghai) Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |